Healthcare Industry News: hemophilia A
News Release - February 8, 2016
Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For ZFN-Mediated Genome Editing Treatment Of MPS IProgram is the Second of the Company's In Vivo Protein Replacement Platform™ Programs to Enter Clinical Development
RICHMOND, Calif., Feb. 8, 2016 -- (Healthcare Sales & Marketing Network) -- Sangamo BioSciences, Inc. (SGMO), the leader in therapeutic genome editing, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for SB-318, a single treatment strategy intended to provide a life-long therapy for Mucopolysaccharidosis Type I (MPS I). The SB-318 IND application is now active and enables Sangamo to initiate a Phase 1/2 clinical study (SB-318-1502) designed to assess the safety, tolerability and potential efficacy of SB-318 in adults with varying severities of MPS I.
SB-318 is Sangamo's second in vivo genome editing application cleared by the FDA; the first being for hemophilia B (SB-FIX). Both programs are based on Sangamo's proprietary In Vivo Protein Replacement Platform (IVPRP™), a single treatment strategy designed to produce stable circulating levels of a therapeutic protein from a patient's liver for the lifetime of the individual. SB-318 treatment is intended to eliminate the need for enzyme replacement therapy (ERT) which is the current standard of care for the majority of patients with MPS I. ERT for MPS I often requires weekly infusions of a recombinant form of the enzyme alpha-L-iduronidase (IDUA) which is missing, or defective, in patients with the disorder. While the infusions take several hours, circulating levels of IDUA are undetectable within hours of the treatment due to the replacement protein's short half-life.
"MPS I, including Hurler syndrome, is tremendously debilitating - and actually life-threatening for affected individuals who struggle with progressive disease even using current therapies," said Chester Whitley, Ph.D., M.D., director of the Gene Therapy Center at the University of Minnesota Medical School and the principal investigator on the proposed SB-318-1502 study. "Our studies in mice predict that this innovative treatment will enable the patient's liver to synthesize stable levels of therapeutic enzyme in the circulation, with the goal of significantly impacting disease symptoms and increasing quality life for patients and their families. The goal of this investigation is to more adequately address the terrible and progressive problems of this condition. Searching for innovative treatments is the center of the academic medicine we practice at the University of Minnesota and we appreciate partnerships, like this one with Sangamo, for allowing us to develop and coordinate this type of clinical trial."
"Our proprietary IVPRP genome editing approach allows us to precisely target and edit the albumin 'safe harbor' locus in the DNA of liver cells, with a single administration, which we expect to result in the durable expression of therapeutic enzyme that would be maintained throughout the patient's life," said Geoff Nichol, M.B., Ch.B., Sangamo's executive vice president of research and development. "We believe this approach provides significant advantages over the current standard of care, as well as conventional AAV gene therapy approaches which are non-integrating and have the potential to "wash out" over time as the patient's liver cells divide and turn over. Ultimately, our target population for this approach will be pediatric patients with MPS I, who will benefit most from a one-time, permanent treatment."
"Genome editing has the potential to change the way medicine is practiced, and we have demonstrated that our zinc finger nuclease technology leads the field in the development of therapeutics for both in vivo and ex vivo applications," said Edward Lanphier, Sangamo's president and chief executive officer. "We are very pleased with the FDA's prompt assessment of our data and their decision to clear our clinical protocol to evaluate our IVPRP approach for the treatment of MPS I. Our goal is to initiate the SB-318-1502 clinical study in mid-2016."
Sangamo remains on track to file additional IND applications for programs employing the IVPRP approach, including MPS II (Hunter syndrome) in the first half of 2016, and hemophilia A, Gaucher disease and Fabry disease in the second half of 2016.
SB-318-1502 is a Phase 1/2 open-label, dose-escalation study in subjects over eighteen years of age with varying severities of MPS I, including Scheie, Hurler-Scheie and Hurler syndrome. The study will begin enrolling up to nine subjects in mid-2016, with the possibility of expanding to 12 subjects, to evaluate the safety, tolerability and efficacy of a single administration of SB-318. The principal investigator, Dr. Whitley, is an established expert in the field of lysosomal storage disorder research with over 30 years of experience in treating patients and evaluating therapies in clinical trials. SB-318 is formulated as adeno-associated virus (AAV) vector preparations encoding the therapeutic alpha-L-iduronidase (IDUA) enzyme and zinc finger nucleases (ZFNs) specific for the albumin locus and will be administered as a single intravenous infusion.
About Sangamo's IVPRP™
The IVPRP approach makes use of the albumin gene locus, a highly expressing and liver-specific genomic "safe-harbor site," that can be edited with zinc finger nucleases (ZFNs) to accept and express any therapeutic gene. The platform is designed to enable the patient's liver to permanently produce circulating, therapeutic levels of a corrective protein product, such as Factor VIII or IX to treat hemophilia, or replacement enzymes to treat lysosomal storage disorders. The ability to permanently integrate the therapeutic gene in a highly specific targeted fashion significantly differentiates Sangamo's IVPRP approach from conventional AAV gene therapy approaches, which are non-integrating and may "wash out" of the liver as cells divide and turn over. Ultimately, the target population for IVPRP programs will be pediatric patients for whom it is critical to be able to produce stable levels of therapeutic protein for the lifetime of the patient. With such a large capacity for protein production (approximately 15g/day of albumin), targeting and co-opting only a very small percentage of the albumin gene's capacity is sufficient to produce the needed replacement protein at therapeutically relevant levels with no significant effect on albumin production. The first two IVPRP clinical programs, for hemophilia B and MPS I, both received unanimous approval from the NIH Recombinant DNA Advisory Committee (RAC) and have been cleared by the FDA, enabling Sangamo to begin Phase 1/2 clinical trials in patients with the disorders.
About MPS I / Hurler Syndrome
Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder, caused by mutations in the gene encoding the alpha-L-iduronidase (IDUA) enzyme, resulting in a deficiency of IDUA which is required for the degradation of the glycosaminoglycans (GAGs), dermatan sulfate and heparin sulfate. The inability to degrade GAGs leads to their accumulation within the lysosomes throughout the body and individuals with this mutation experience multi-organ dysfunction and damage. Depending on the severity of the mutations and degree of residual enzyme activity, affected individuals may develop organomegaly, joint stiffness, skeletal deformities, corneal clouding, hearing loss and mental retardation. Three forms of MPS I, in order of increasing severity, include Scheie, Hurler-Scheie and Hurler syndromes. According to the National MPS Society, one in every 500,000 births in the U.S. will result in Scheie syndrome, one in every 115,000 births in Hurler/Scheie, and one in every 100,000 births results in Hurler syndrome. There are approximately 2,000 MPS I patients in the U.S. The current therapies for individuals with MPS I include hematopoietic stem cell transplantation (HSCT) for those with the most severe form of the disease (Hurler) and enzyme replacement therapy (ERT) for patients with the attenuated forms of the disease (Hurler-Scheie, Scheie).
Sangamo BioSciences, Inc. is focused on Engineering Genetic Cures® for monogenic and infectious diseases by deploying its novel DNA-binding protein technology platform in therapeutic genome editing and gene regulation. The Company's proprietary In Vivo Protein Replacement Platform™ (IVPRP™) approach is focused on monogenic diseases, including hemophilia And lysosomal storage disorders. In addition, Sangamo has a Phase 2 clinical program to evaluate the safety and efficacy of novel ZFP Therapeutics® for the treatment of HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington's disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at www.sangamo.com.
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references relating to research and development of novel ZFNs and therapeutic applications of Sangamo's ZFP technology platform, the potential of Sangamo's ZFP technology to treat hemophilia B, hemophilia A and lysosomal storage disorders, including MPS I, MPS II, Gaucher disease and Fabry disease, the expected timing of trial enrollment for SB-318-1502 and filing of IND applications for hemophilia A, MPS II Gaucher disease and Fabry disease, the impact of the SB-318-1502 clinical trial on the field of genetic medicine, the potential benefits of SB-318 as treatment for pediatric patients, and the safety and efficacy of the approach of using ZFN-mediated genome editing. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of our clinical trials, whether the clinical trials will validate and support the safety, tolerability and efficacy of ZFNs, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. For a more detailed discussion of these and other risks, please see Sangamo's public filings with the Securities and Exchange Commission, including the risk factors described in its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.
Source: Sangamo BioSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.